Skip to main content Skip to search Skip to main navigation

EC: New Entries in the MDCG Borderline Manual

The Medical Device Coordination Group (MDCG) has updated its manual on the classification of products that are on the borderlines between medtech and other regulatory categories (Version 4).

The following newly added cases illustrate current regulatory decisions on qualification and classification:

  • Red blood cell additive solutions containing adenine
    Medical Device, Class III
    Adenine exerts metabolic/pharmacological effects on RBCs; therefore, the solution is classified as part of a Class III device.
  • Dual-action cream with menthol and capsaicin
    Not a medical device
    Principal mode of action is pharmacological (via receptor activity); classified as a medicinal product.
  • Lactose vaginal tablets
    Not a medical device
    Mode of action is metabolic, based on lactic acid bacteria metabolizing lactose into lactic acid.
  • Microabrasion dental stain removers (tooth whitening)
    Not a medical device
    Purely cosmetic purpose (aesthetic improvement), no proven medical benefit.
  • Medical examination table covers
    Medical device
    Intended to prevent disease transmission (infection prevention), thus meeting the definition of a medical device.
  • Mobile sterile air system
    Not a medical device
    Controls the environment (air purification/laminar flow), without direct action in or on the human body.

The updates highlight the strict distinction between medical purpose and cosmetic, pharmacological, or purely environmental functions. Manufacturers must provide robust scientific evidence of the principal mode of action to ensure correct regulatory qualification.


Source:

EC: Manual on borderline and classification for medical devices under Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next